Prevalence of Anti-HCV Antibody Among the General Population in Mainland China Between 1991 and 2015: A Systematic Review and Meta-analysis
Sign Up to like & getrecommendations! Published in 2019 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofz040
Abstract: Abstract Our study aims to estimate the burden of hepatitis C virus (HCV) infection among the general population in Mainland China. We searched 4 databases for studies of the prevalence of anti-HCV antibody among the… read more here.
Keywords: hcv antibody; anti hcv; prevalence anti;
Identification of Risk Factors for Testing of Hepatitis C in Non-Birth Cohort Patients: Is Universal Screening Necessary?
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Addiction Medicine"
DOI: 10.1097/adm.0000000000000702
Abstract: OBJECTIVES CDC reported that 45% of Hepatitis C (HCV) infected people denied known risk factors. Electronic health record RF-based, non-Birth Cohort (born outside of years 1945-1965) screening is challenging as risk factors are often input… read more here.
Keywords: hcv antibody; risk; risk factors; birth cohort ... See more keywords
Rapid decline of anti‐hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV‐infected men who have sex with men
Sign Up to like & getrecommendations! Published in 2018 at "HIV Medicine"
DOI: 10.1111/hiv.12602
Abstract: OBJECTIVES Following clearance of incident hepatitis C virus (HCV) infections, HCV antibody levels may decline, resulting in seroreversion. It is unclear to what extent HCV antibody level trajectories differ between patients with treatment-induced sustained virological… read more here.
Keywords: hcv antibody; treatment; infection; hcv ... See more keywords
HCV elimination in a Swiss opioid agonist therapy programme - a cohort study.
Sign Up to like & getrecommendations! Published in 2022 at "Swiss medical weekly"
DOI: 10.57187/smw.2022.40009
Abstract: BACKGROUND In opioid agonist therapy (OAT) programmes, chronic hepatitis C is highly prevalent and directly observed therapy guarantees optimal adherence. Since 2017, all patients with chronic hepatitis C in Switzerland can be treated with pangenotypic… read more here.
Keywords: therapy; hcv; hepatitis; hav hbv ... See more keywords